Search results
Results from the WOW.Com Content Network
Cabotegravir in combination with rilpivirine is indicated for the treatment of human immunodeficiency virus type-1 (HIV-1) in adults. [1] [7] The combination injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/mL) with their current antiretroviral treatment, and when the virus has not developed resistance to ...
[4] [8] [9] It is the first FDA-approved injectable, complete regimen for HIV-infected adults that is administered once a month. [4] [5] It is also approved for use in Canada. [1] In the European Union, the two medications are approved separately and have different brand names: Vocabria (for cabotegravir) and Rekambys (for rilpivirine). [10 ...
In 2012, the FDA approved the drug for use as pre-exposure prophylaxis (PrEP), based on growing evidence that the drug was safe and effective at preventing HIV in populations at increased risk of infection. [41] The FDA has approved two additional medications for PrEP since then, approving Descovy in 2019 and Cabotegravir (Apretude) in 2021. [4 ...
cabotegravir (brand names Apretude [as a single agent indicated for PrEP]; and Vocabria/Cabenuva [when co-administered with rilpivirine for HIV treatment – in partnership with Janssen Pharmaceuticals]) Protease inhibitors: fosamprenavir (brand names Lexiva and Telzir) nelfinavir (brand name Viracept) Entry inhibitors:
The first Girls California Live 23 Tournament will include 100 teams and scores of players who are already being recruited by Division I programs in an event that is approved by the NCAA and the ...
Normalcy might be returning to City Section basketball, since 14-time City champion Westchester (16-9, 9-0) is back on top as the favorite to win the Open Division championship.
Players and coaches for the 2023-24 Cathedral Prep girls basketball team pose with a sign that indicated the Ramblers were headed to Saturday's PIAA Class 5A championship at Hershey's Giant Center.
Lenacapavir was approved for medical treatment in the European Union in August 2022, [10] [12] in Canada in November 2022, [5] [6] and in the United States in December 2022. [9] [11] [13] [14] It is the first of a class of drugs called capsid inhibitors to be approved by the US Food and Drug Administration (FDA) for treating HIV/AIDS. [11] [15]